SecBot SecBot
PRESS-RELEASE ·Filed May 27, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The Priority Review acceptance and absence of an AdCom are strong positive signals. Monitor for any FDA review updates or potential manufacturing/CMC questions ahead of the November 27 PDUFA. The stock may re-rate upward as approval probability increases. Watch for any competitive developments or regulatory setbacks in Europe.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$66.44
T+0 close · May 27, 2026 · via day close
Latest settled
+24.83%
T+60 · $82.94
Vs SPY
+22.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 27 $66.44entry
  2. T+1 · 6mo ago +3.03%α +2.47% · $68.45
  3. T+5 · 6mo ago −3.85%α −5.06% · $63.88
  4. T+20 · 5mo ago +4.89%α +6.79% · $69.69
  5. T+60 · 3mo ago +24.83%α +22.95% · $82.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced FDA acceptance of its NDA with Priority Review for BBP-418 (LGMD2I/R9), with a PDUFA date of November 27, 2026. The FDA is not planning an advisory committee meeting, and the company is poised to launch upon approval. This is a major regulatory milestone for a first-in-class therapy addressing a significant unmet need in a rare, progressive muscular dystrophy.

Key Facts

  • FDA accepted NDA for BBP-418 with Priority Review; PDUFA target action date November 27, 2026.
  • FDA not currently planning an advisory committee meeting to discuss the application.
  • BBP-418 met all primary and secondary endpoints in Phase 3 FORTIFY trial at 12-month interim analysis.
  • If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD.
  • Approximately 7,000 individuals in the U.S. and Europe live with LGMD2I/R9 and other addressable α-dystroglycanopathies.
  • BBP-418 has Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from FDA; may qualify for a Priority Review Voucher upon approval.
  • Company intends to initiate clinical studies in patients under 12 years old and in LGMD2M/R13 and LGMD2U/R20.

Financial Impact

First-in-class therapy for ~7,000 patients in U.S./Europe; potential for significant revenue if approved, with pricing typical for rare disease drugs (often $100K-$500K+/year). No financial terms disclosed.

revenuepipeline value

Risk Factors

  • FDA could issue a Complete Response Letter (CRL) at PDUFA date, particularly on CMC or safety grounds.
  • Commercial uptake depends on pricing, reimbursement, and physician adoption for a novel therapy in a small patient population.
  • Clinical data from ongoing pediatric and additional indication studies could reveal safety or efficacy issues.
  • Competition from other LGMD therapies in development could emerge.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3301817

Track record

38 reports on BBIO

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 27, 2026